Featured content
Six assay requirements every researcher using NAMs should know
As NAMs become more widely used in drug discovery, assays must meet the demands of more complex models. Discover six requirements for reliable, reproducible and biologically meaningful data.
ArticlePROTACs vs molecular glues: which degrader fits your target?
PROTACs and molecular glues can both remove disease-associated proteins, but choosing between them is not simple. Our new Discovery Toolkit compares the options to help discovery teams choose the right strategy.
ReportBuilding biomarkers that drug developers can rely on
Discover how integrated technologies, multiomic approaches and AI are helping researchers translate complex biological signals into actionable tools for drug development and patient care.
ArticleHow rare genetic variants could uncover new drug targets
What if extreme levels of common traits have a different genetic basis? New research suggests rare, large-effect variants could help explain the extremes and identify potential drug targets.
News
NewsInsilico launches specialist AI models for drug discovery chemistry
Insilico Medicine has unveiled a suite of compact, domain-trained AI models targeting ADMET prediction, retrosynthesis and target activity across GPCR and kinase panels, claiming state-of-the-art results on more than 70 benchmarks.
NewsPatient-derived tumour organoid biobank maps cancer gene dependencies
A biobank of 256 patient-derived tumour organoids, combined with genome-wide CRISPR–Cas9 screening, has produced a detailed map of cancer gene dependencies across five tumour types, revealing both shared vulnerabilities and mutation-specific targets with implications for precision oncology.
NewsEngineered tRNAs and lipid nanoparticles target nonsense mutation cystic fibrosis
A preclinical study combining chemically modified suppressor tRNAs with inhaled lipid nanoparticles has restored functional CFTR protein production across bronchial epithelial cells, mouse models and patient-derived organoids, offering a potential new therapeutic strategy for nonsense mutation-driven cystic fibrosis.
NewsNew LOX target discovery could help overcome chemotherapy-resistant breast cancer
A preclinical study has identified lysyl oxidase as an intracellular survival factor in triple-negative breast cancer, with researchers demonstrating that sequentially blocking LOX and a compensatory ferroptosis defence pathway significantly suppresses tumour growth without chemotherapy.
From our partners
Webinar
What it really takes to turn cancer discoveries into new therapies
Five leading cancer researchers from across genomics, proteomics, cell biology, chemical biology and gene therapy dig into what’s driving cancer drug discovery forward and what’s still holding progress back.
Webinar
Oligonucleotide therapeutics safety considerations across drug development
As oligonucleotide therapeutics continue to advance, their safety assessment presents challenges that differ from traditional drug modalities. Discover how nonclinical safety studies, evolving regulatory expectations and real-world case examples can help you navigate these challenges with greater confidence.
Opinion and interviews
The global push to reduce animal testing in drug development
Non-animal methods are already used throughout early drug discovery, yet animal testing continues to dominate regulatory safety assessment. Recent initiatives suggest change is coming, but significant scientific and practical challenges remain.
- Previous
- Next
Join now
Unlock exclusive industry insights
- Bookmark articles and resources to access anytime
- Enjoy free access to industry leading resources, webinars and insights
- Stay informed with the latest news and breakthroughs
- Receive updates and recommendations tailored to your research interests
Upcoming Webinars
Webinar
Meeting ethical & regulatory requirements when using human biological specimens
Whether you source, purchase or work with human biospecimens, understanding today’s ethical and regulatory expectations is essential. Join this webinar to explore informed consent, privacy and the principles that support responsible research.
Webinar
Building better therapeutic antibodies: the science, progress and problems to solve
As therapeutic antibodies become more complex, where is the field making real progress and which problems are proving hardest to solve? Hear leading experts share their perspectives.
Webinar
Oligonucleotide therapeutics safety considerations across drug development
As oligonucleotide therapeutics continue to advance, their safety assessment presents challenges that differ from traditional drug modalities. Discover how nonclinical safety studies, evolving regulatory expectations and real-world case examples can help you navigate these challenges with greater confidence.
Webinar
From antibody discovery to development: long-read sequencing in practice
As sequencing continues to grow in importance across biotherapeutic discovery and development, where can it make the biggest impact and how can fragmented workflows be overcome?
Webinar
What it really takes to turn cancer discoveries into new therapies
Five leading cancer researchers from across genomics, proteomics, cell biology, chemical biology and gene therapy dig into what’s driving cancer drug discovery forward and what’s still holding progress back.
Meeting ethical & regulatory requirements when using human biological specimens
Building better therapeutic antibodies: the science, progress and problems to solve
Oligonucleotide therapeutics safety considerations across drug development
From antibody discovery to development: long-read sequencing in practice
What it really takes to turn cancer discoveries into new therapies
On-demand Webinars
- Previous
- Next
